Article Versions Notes

Matovinović M, Belančić A, Jug J, Mustač F, Sirovica M, Santini M, Bošnjaković A, Lovrić M, Lovrić Benčić M. Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations? Diabetology. 2024; 5(1):26-39. https://doi.org/10.3390/diabetology5010003

Matovinović, Martina, Andrej Belančić, Juraj Jug, Filip Mustač, Maja Sirovica, Mihovil Santini, Anja Bošnjaković, Mario Lovrić, and Martina Lovrić Benčić. 2024. "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?" Diabetology 5, no. 1: 26-39. https://doi.org/10.3390/diabetology5010003

Matovinović, M., Belančić, A., Jug, J., Mustač, F., Sirovica, M., Santini, M., Bošnjaković, A., Lovrić, M., & Lovrić Benčić, M. (2024). Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations? Diabetology, 5(1), 26-39. https://doi.org/10.3390/diabetology5010003